Sonnet biotherapeutics provides fiscal year 2024 first quarter business and earnings update

Successfully raised approximately $4.55 million in gross proceeds through an underwritten public offering extensive preclinical data on son-1210 published in frontiers in immunology received approval and executed agreement to sell new jersey state net operating losses (nols) for expected net proceeds of $4.3 million enrollment of the phase 1b portion of the son-080 trial in chemotherapy-induced peripheral neuropathy (cipn) has completed princeton, nj / accesswire / february 14, 2024 / sonnet biotherapeutics holdings, inc. (nasdaq:sonn) ("sonnet" or the "company"), a clinical-stage biopharmaceutical company developing targeted immunotherapeutic drugs for cancer, announced today its financial results for the three months ended december 31, 2023 and provided a business update. "this last quarter set the stage for an exciting year across sonnet's pipeline, highlighted by the progress of the combination study of son-1010 and atezolizumab in platinum-resistant ovarian cancer (proc), where we continue to expect safety data during the first half of 2024.
SONN Ratings Summary
SONN Quant Ranking